Trial Profile

A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Dexamethasone; Lenalidomide
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms KEYNOTE-185
Sponsors Merck Sharp & Dohme

Most Recent Events

19 Nov 2021 This trial has been completed in Spain (end date of the trial: 13 July 2021), according to European Clinical Trials Database record.
09 Jul 2021 This trial has been completed in Ireland (Date of the global end of the trial: 13 July 2021).
02 Dec 2020 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com